Design, synthesis, and biological activity of novel pomalidomide linked with diphenylcarbamide derivatives-Reference-Cited by-同舟云学术

Design, synthesis, and biological activity of novel pomalidomide linked with diphenylcarbamide derivatives

Published:2022-01-01 Issue:1 Volume:28 Page:174-180
ISSN:2191-0197
Container-title:Heterocyclic Communications
language:en
Short-container-title:

Author:

Sun Bin¹,Liu Xiaofei²³,Ji Tao²³,Zhan Xiaoguang²³,Mao Longfei²³,Deng Peng²,Shi Lin⁴

Affiliation:

1. College of Chemistry, Chemical Engineering and Materials Science, Collaborative Innovation Center of Functionalized Probes for Chemical Imaging in Universities of Shandong, Key Laboratory of Molecular and Nano Probes, Ministry of Education, Shandong Provincial Key Laboratory of Clean Production of Fine Chemicals, Shandong Normal University, 88 East Wenhua Road , Jinan 250014 , PR China

2. Key Laboratory of Agro-Products Processing Technology of Shandong Province, Key Laboratory of Novel Food Resources Processing, Ministry of Agriculture, Institute of Agro-Food Science and Technology, Shandong Academy of Agricultural Sciences , Jinan 250100 , China

3. Jinan Asia Pharma Tech Co. Ltd , Jinan 250101 , China

4. Department of Ultrasound Diagnosis and Treatment Department, Shandong Provincial Hospital Affiliated to Shandong First Medical University , Jinan 250021 , China

Abstract

Abstract Based on 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione as a raw material, a series of novel pomalidomide linked with diphenylcarbamide derivatives were synthesized through several step reactions of substitution, click reaction, and addition reaction. The structures of these compounds were confirmed by 1H NMR, 13C NMR, and MS. We discovered that some of the compounds are capable of suppressing indoleamine pyrrole-2,3-dioxygenase-1 activities in in vitro experiments, in which the inhibitory activity of 5b reached the level of benefits.

Publisher

Walter de Gruyter GmbH

Subject

Organic Chemistry

Link

https://www.degruyter.com/document/doi/10.1515/hc-2022-0155/pdf

Reference16 articles.

1. Gao S, Zou F, Zheng L, Wang Y, Feng X, Liu D, et al. Efficacy and mechanism of KRAS G12C PROTAC in inhibiting the proliferation of pancreatic cancer cells. J Pharm Biopharm Res. 2021;3:176–84.

2. Mh A, Wz A, Yw A, Dy A, Ty A, Yy A, et al. Discovery of the first potent proteolysis targeting chimera (PROTAC) degrader of indoleamine 2,3-dioxygenase 1. Acta Pharm Sin B. 2020;10:1943–53.

3. Cecchini C, Tardy S, Ceserani V, Theurillat JP, Scapozza L. Exploring the Ubiquitin-Proteasome System (UPS) through PROTAC Technology. Chimia. 2020;74:274–7.

4. Lai AC, Momar T, Doris H, Jemilat S, Saul JF, Eunhwa K, et al. Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL. Angew Chem (Int Ed Engl). 2018;55:807–10.

5. Wei HB, Wang YT, Sun F, Shao Y, Zhuo J, Pang K, et al. The Application and Progress of Chimeric Molecules (DHT-PROTAC) in Prostate Cancer. Prog Mod Biomed. 2014;14:590–2.